Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 16 systematic review(s)/meta-analysis(es). ^[1-16]
• Brolucizumab demonstrated significant improvement in best-corrected visual acuity (BCVA (retinal central subfield thickness (CSFT)) compared to other anti-vascular endothelial growth factor (VEGF) agents, particularly Ranibizumab, with moderate-certainty evidence indicating superior BCVA outcomes at 12 months.
• In terms of central subfield thickness (CST), Brolucizumab showed a greater reduction at 24 months compared to Ranibizumab, suggesting superior anatomical improvements in patients with neovascular age-related macular degeneration (nAMD).
• Brolucizumab required fewer injections compared to Ranibizumab and Aflibercept when administered in an every 12 weeks (every 4 weeks) (Q12W (Q4W))/ every 8 weeks (every 4 weeks) (Q8W (Q4W)) regimen, highlighting its potential for reduced treatment burden.
• Brolucizumab was effective in improving CST in patients switching from other anti-VEGF agents, although there was a small worsening in BCVA, indicating it could be beneficial for recalcitrant nAMD cases.
• Brolucizumab was associated with a higher incidence of serious ocular adverse events, particularly retinal vasculitis and vascular occlusion, with an average onset of 19.4 days after injection. These events were more common in older patients (mean age 77.6 years) and predominantly in females (77.8%).
• Faricimab showed a comparable safety profile to other anti-VEGF agents, with a significant reduction in the risk of serious ocular adverse events (SOAEs) compared to Brolucizumab in quarterly dosing.
• Ocular adverse events were generally rare across the studies, but reporting inconsistencies made it difficult to draw comprehensive comparisons across different anti-VEGF treatments.